Abstracts tagged "Economics"

Abstract Number: 2416 • ACR Convergence 2025
Direct and Indirect Costs Associated with Damage Accrual: Results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
Megan Barber¹, John Hanly², Murray Urowitz³, Ian Bruce⁴, Yvan St-Pierre⁵, Caroline Gordon⁶, Sang-Cheol Bae⁷, Juanita Romero-Diaz⁸, Francisco Sanchez-Guerrero⁹, Sasha Bernatsky¹⁰, Daniel Wallace¹¹, David A. Isenberg¹², Anisur Rahman¹², Joan Merrill¹³, Paul Fortin¹⁴, Dafna D. Gladman¹⁵, Michelle Petri¹⁶, Ellen Ginzler¹⁷, Mary Anne Dooley¹⁸, Rosalind Ramsey-Goldman¹⁹, Susan Manzi²⁰, Andreas Jönsen²¹, Graciela Alarcón²², Ronald van Vollenhoven²³, Cynthia Aranow²⁴, Meghan mackay²⁵, Guillermo Ruiz-Irastorza²⁶, S. Sam Lim²⁷, Murat Inanç²⁸, Kenneth Kalunian²⁹, Soren Jacobsen³⁰, Christine Peschken⁸, Diane Kamen³¹, Anca Askanase³² and Ann Clarke¹, ¹Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²Dalhousie University, Halifax, NS, Canada, Halifax, NS, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴Centre for Public Health, Faculty of Medicine, Health and Life Sciences, Queen’s University Belfast, Belfast, United Kingdom, ⁵Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁶Department of Inflammation and Ageing, College of Medicine and Health, University of Birmingham, Birmingham, United Kingdom, ⁷Hanyang University Medical Center, Seoul, South Korea, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹University Health Network/Sinai Health system, Toronto, ON, Canada, ¹⁰Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ¹¹Cedars Sinai Medical Center, Studio City, CA, ¹²University College London, London, United Kingdom, ¹³Oklahoma Medical Research Foundation, Oklahoma City ⁷³¹⁰⁴, OK, ¹⁴Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ¹⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ¹⁶Johns Hopkins University School of Medicine, Timonium, MD, ¹⁷SUNY Downstate Health Sciences University, New York, NY, ¹⁸UNC physician network, Chapel Hill, NC, ¹⁹Northwestern University Feinberg School of Medicine, Chicago, IL, ²⁰Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA, ²¹Department of Clinical Sciences, Lund University, Lund, Sweden, ²²The University of Alabama at Birmingham, Oakland, CA, ²³Department of Rheumatology, Amsterdam University Medical Centre, Amsterdam, Netherlands, ²⁴Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, ²⁵Feinstein Institutes for Medical Research, Manhasset, NY, ²⁶Biobizkaia Health Research Institute, Barakaldo, Spain, ²⁷Emory University School of Medicine, Atlanta, GA, ²⁸Istanbul University, Istanbul, Turkey, ²⁹UC San Diego, La Jolla, CA, ³⁰Rigshospitalet, Copenhagen, Denmark, ³¹Medical University of South Carolina, Johns Island, SC, ³²Columbia University Medical Center, New York, NY
Background/Purpose: We reported partial direct healthcare costs associated with damage accrual in the SLICC Inception Cohort (Barber M. Arthritis Care Res 2020;72:1800). We have supplemented…
Abstract Number: 2408 • ACR Convergence 2025
Direct Medical Cost Burden of Cutaneous Lupus Erythematosus (CLE): A Comparison with Psoriasis, Atopic Dermatitis, and a General Population
Joseph F Merola¹, Catherine Mak², Tiange Tang², Tricia Li², Margaret K Moseley², Janine Gaiha-Rohrbach² and Feng Zeng², ¹Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ²Biogen, Cambridge, MA
Background/Purpose: Cutaneous lupus erythematosus (CLE) is an autoimmune disease primarily manifesting in skin that can significantly impact patients’ quality of life. Current understanding of the…
Abstract Number: 2185 • ACR Convergence 2025
The Evolving Digital Landscape of Social Media among Rheumatology Professionals: A Global Analysis by the EULAR SoMeR Study Group
Latika Gupta¹, Manali Sarkar², Jeffrey Sparks³, Loreto Carmona⁴, Vikas Agarwal⁵, Carlo Vinicio Caballero Uribe⁶, Dzifa Dey⁷, Chris Edwards⁸, Francis BERENBAUM⁹ and Elena Nikiphorou¹⁰, ¹School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham; Royal Wolverhampton NHS Trust; Centre for Musculoskeletal Research, School of Biological Sciences, The University of Manchester, Manchester; Francis Crick Institute, London, Birmingham, UK, United Kingdom, ²Sir H. N. Reliance Foundation Hospital and Research Centre, Mumbai, Maharashtra, India., Mumbai, Maharashtra, India, ³Brigham and Women's Hospital, Boston, MA, ⁴Instituto de Salud Musculoesquelética (InMusc), Madrid, Spain, ⁵Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ⁶Department of Medicine, Hospital Universidad del Norte, Barranquilla, Atlantico, Colombi, Barranquilla, Colombia, ⁷Rheumatology Unit Department of Medicine and Therapeutics, Korle bu Teaching Hospital, University of Ghana Medical School, Accra, Ghana, ⁸University Hospital Southampton, Southampton, United Kingdom, ⁹Sorbonne University/Inserm/AP-HP/⁴Moving Biotech, Paris, France, ¹⁰King's College London, London, United Kingdom
Background/Purpose: Social media (SoMe) has become an indispensable tool in healthcare, providing platforms for information sharing, networking, and education. However, its use presents challenges including…
Abstract Number: 1929 • ACR Convergence 2025
Economic Burden of Macrophage Activation Syndrome (MAS) in Patients with Still’s Disease (Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult-onset Still’s Disease (AOSD)): Analysis of a US National Administrative Claims Database
Michael Marrone¹, Christopher McPherson² and Abiola Oladapo³, ¹Sobi Inc., Mt Pleasant, SC, ²Sobi, University City, MO, ³Sobi INC, Waltham, MA
Background/Purpose: Macrophage activation syndrome (MAS) is a severe, life-threatening complication of rheumatologic disease. MAS is a form of secondary hemophagocytic lymphohistiocytosis which occurs most frequently…
Abstract Number: 1376 • ACR Convergence 2025
A Systematic Literature Review on the Economic Burden of Sjögren’s Disease
Nora Sandorfi¹, Lisa Shea², Alexander Keenan², Elizabeth Adamson², Federico Zazzetti³, Soumya Chakravarty⁴, Donna Gotshall⁵, Jyotika Gandhi⁶, Sandip Ranjan⁶ and Esen Akpek⁷, ¹University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, ²Johnson & Johnson, Horsham, PA, USA, Horsham, PA, ³Johnson & Johnson, Horsham, PA, USA, Ambler, PA, ⁴Johnson & Johnson, Horsham, PA, USA; Drexel University College of Medicine, Philadelphia, PA, USA, Villanova, PA, ⁵Sjögren’s Disease Patient, Hickory, NC, USA, Hickory, NC, ⁶Putnam Associates, Gurugram, India, Gurugram, India, ⁷Johns Hopkins Jerome L. Greene Sjögren's Syndrome Center, Baltimore, MD USA, Baltimore, MD
Background/Purpose: Sjögren’s disease (SjD) is a chronic systemic autoantibody driven disorder characterized by glandular dysfunction that typically presents with oral and ocular dryness, fatigue, and…
Abstract Number: 1366 • ACR Convergence 2025
Cost Per Responder Analysis of Certolizumab Pegol Versus Adalimumab in Patients with Moderate to Severe Active Rheumatoid Arthritis and High Rheumatoid Factor Levels: A Payer Perspective from Canada and Brazil
Rémi Marty¹, Baran Ufuktepe², Nicola Tilt³, Flore Decuypere⁴, Angela Blake³, Sandeep Kiri³ and Mohammed Soomro³, ¹UCB Pharma, Brussels, Belgium, Anderlecht, Belgium, ²UCB Pharma Istanbul, Turkey, istanbul, Turkey, ³UCB Pharma, Slough, United Kingdom, Slough, United Kingdom, ⁴UCB Pharma Brussels, Belgium, Brussels, Belgium
Background/Purpose: According to the 2022 EULAR recommendations for the management of rheumatoid arthritis (RA), the presence of rheumatoid factor (RF), particularly at high levels, is…
Abstract Number: 1365 • ACR Convergence 2025
Economic impact of early treatment and strict disease control in rheumatoid arthritis: a cost-minimization approach concerning biological therapy
Raianni Rúbia Pacheco Silva¹, Daniel da Silva Pereira Curado², Paula Cristina Montina², Everton Nunes da Silva³, Ana Paula Monteiro Gomides², Rina Dalva Neubarth Giorgi⁴, Leticia Rocha Pereira⁵, Sebastião Cezar Radominski⁶, Ivanio Alves Pereira⁷, Maria Fernanda Brandão de Resende Guimarães⁸, Manoel Barros Bertolo⁹, Paulo Louzada Junior¹⁰, Maria de Fátima Lobato da Cunha Sauma¹¹, Karina Rossi Bonfiglioli⁵, Claiton Viegas Brenol¹², Geraldo da Rocha Castelar Pinheiro¹³, Cleandro Pires de Albuquerque² and Licia Maria Henrique da Mota¹⁴, ¹Universidade de Brasília, Brasília, Distrito Federal, Brazil, ²Universidade de Brasília, Brasília, Brazil, ³Universidade de Brasília, brasilia, Brazil, ⁴IAMSPE, São Paulo, Brazil, ⁵Hospital do Servidor Público Estadual de São Paulo, São Paulo, Brazil, ⁶UFPR, Curitiba, Brazil, ⁷UFSC, Florianopolis, Brazil, ⁸UFMG, Belo Horizonte, Brazil, ⁹Unicamp, Campinas, Brazil, ¹⁰USP-RP, Ribeirão Preto, Brazil, ¹¹UFPA, Belem, Brazil, ¹²UFRGS, Porto Alegre, Brazil, ¹³UERJ, Rio de Janeiro, Brazil, ¹⁴UNB, Brasilia, Distrito Federal, Brazil
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, progressive, potentially disabling autoimmune disease, with substantial economic burden, particularly related to its high-cost pharmacological treatment. Early treatment,…
Abstract Number: 0525 • ACR Convergence 2025
Cost-of-Illness Among Newly Diagnosed Patients with Psoriatic Arthritis in Sweden
Sofia Wittgren¹, Sofia Exarchou², Daniela Di Giuseppe³, Ulf Lindström⁴, Tor Olofsson¹, Lennart T. H. Jacobsson⁴, Johan Askling³ and Johan Karlsson Wallman¹, ¹Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, Skane Lan, Sweden, ²Lund University, Åkarp, Skane Lan, Sweden, ³Karolinska Institutet, Department of Medicine Solna, Clinical Epidemiology Division, Stockholm, Stockholms Lan, Sweden, ⁴Gothenburg University, Sahlgrenska Academy, Department of Rheumatology and Inflammation Research, Gothenburg, Vastra Gotaland, Sweden
Background/Purpose: Up-to-date information on the cost-of-illness of psoriatic arthritis (PsA) is important for healthcare/social insurance system budgeting and to highlight unmet needs in PsA care.…
Abstract Number: 2500 • ACR Convergence 2025
Greater Economic Burden and Healthcare Resource Utilization in Patients with Systemic Sclerosis With Versus Without Interstitial Lung Disease: Results from a Systematic Literature Review
Emily Glowienka¹, Sarah Nickolls², Kevin Coady¹, Eesha Kodi³, Ian Steinfield¹, Florence Wilson³, Alicia N. Pepper³, Svetlana I. Nihtyanova⁴, Roger A. Levy⁵ and Daniel Moldaver⁶, ¹Precision AQ, Boston, MA, ²GSK, Research & Development, Stevenage, United Kingdom, ³Precision AQ, Vancouver, BC, Canada, ⁴GSK, Clinical Sciences, Research & Development, London, United Kingdom, ⁵GSK, Specialty Care, Global Medical Affairs, Collegeville, PA, ⁶GSK, Global Real-World Evidence & Health Outcomes Research, Toronto, ON, Canada
Background/Purpose: SSc is a rare autoimmune connective tissue disorder; up to 64% of patients with SSc develop interstitial lung disease (ILD), which can result in…
Abstract Number: 0212 • ACR Convergence 2024
Costs of Hospitalization in Patients with SLE: An Analysis of the National Inpatient Sample
Brandon Blau¹, Kelsey Gripp¹, Catherine MacLean² and Bella Mehta², ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with significant health care utilization, medical costs, and increased risk of hospitalization. We aimed to characterize the reasons…
Abstract Number: 1018 • ACR Convergence 2024
Analysis of Medication Usage and Monthly Costs in Hospitalized Patients with Rheumatic Diseases: A Retrospective Observational Study
Daniela Alejandra Salcedo-Soto¹, Ana Cecilia Bardan-Inchaustegui², Pablo Gamez-Siller³, Deynna Montserrat Lara Mendez⁴, Diana Elsa Flores-Alvarado⁵, Jorge Esquivel-Valerio⁶, Jesus Cardenas-de la Garza² and Dionicio Galarza-Delgado⁷, ¹Hospital Universitario Dr Jose Eleuterio Gonzalez, Monterrey, Mexico, ²Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ³Facultad de Medicina UANL, Monterrey, Nuevo León, Mexico, ⁴Hospital Universitario Dr José Eleuterio González, Monterrey, Nuevo León, Mexico, ⁵Hospital Universitario Jose Eleuterio Gonzalez, Monterrey, Nuevo León, Mexico, ⁶Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, MONTERREY, Mexico, ⁷UANL Hospital Universitario, Monterrey, Nuevo León, Mexico
Background/Purpose: Costs associated with rheumatic diseases significantly affect a considerable portion of patients’ income. The monthly income of northeastern Mexican families has been reported to…
Abstract Number: 1046 • ACR Convergence 2024
Shifting Paradigms in Drug Spending: A Study of Medicare Part D versus Emerging Pharmacy Models in Rheumatology
Katherine Schoeffler, Stephanie Beveridge, Max Bouvette, Veera Durga Vaishnavi Kurra, Reema Moussa, Ryan Johnson, Camille Goerend, Nimrah Bader and Ryan Nipp, University of Oklahoma College of Medicine, Oklahoma City, OK

Background/Purpose: Recent policy changes and competitive alternative drug pricing models present the potential for medication cost savings. In this study, we sought to assess the…
Abstract Number: 1049 • ACR Convergence 2024
Very Low Uptake of Biosimilar Adalimumab in the First 9 Months of Availability in Rheumatology
Eric Roberts¹, Gabriela Schmajuk² and Jinoos Yazdany³, ¹University of California, San Francisco, SF, CA, ²UCSF / SFVA, San Francisco, CA, ³UCSF, San Francisco, CA
Background/Purpose: In 2021, over 300,000 patients in the United States used adalimumab, making it one of the highest-grossing drugs globally. In 2023, patent exclusivity for…
Abstract Number: 1870 • ACR Convergence 2024
Costs and Healthcare Resource Utilization Associated with Inpatient and Day Hospitalizations of Patients with Lupus and Psychiatric Manifestations in France
Nicoleta Petrica¹, Nathan Cohen¹, Maria Pini¹, Minjee Park², Mathieu Rosé³ and Jean-Francois Ricci², ¹Alira Health, Paris, France, ²Alira Health, Basel, Switzerland, ³Alira Health, Barcelone, Spain
Background/Purpose: Lupus, a rare chronic autoimmune disorder, severely impacts patients' quality of life, productivity, and survival, placing a heavy burden on the healthcare system. Up…
Abstract Number: 1904 • ACR Convergence 2024
Evaluation of the Economic Burden of Psoriatic Arthritis: Assessment of Direct Costs Using National Administrative Databases at National Level
Wilson Bautista-Molano¹, Ingrid Ramirez-bolivar², Cristina Pinilla-Forero³ and Luz A Ruiz⁴, ¹University Hospital Fundación Santa Fe de Bogotá, Bogotá, Colombia, ²Janssen, Bogotá, Colombia, ³Janssen, Bogotá, ⁴CODENTMED, Bogotá, Colombia
Background/Purpose: Psoriatic arthritis (PsA) is a high-cost disease due to its significant impact on patients' quality of life and the extensive resources required for its…

1
2
3
…
9
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].